Incentives for drug development - The curious case of colchicine

New England Journal of Medicine

Volumn 362, Issue 22, 2010, Pages 2045-2047

  Kesselheim, Aaron S ^a   Solomon, Daniel H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLCHICINE; COLCRYS; NEW DRUG; PROBENECID; THALIDOMIDE; UNCLASSIFIED DRUG;

ACUTE DISEASE; BIRTH DEFECT; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; FAMILIAL MEDITERRANEAN FEVER; FOOD AND DRUG ADMINISTRATION; GOUT; HEALTH CARE POLICY; HUMAN; LEPROSY; MULTIPLE MYELOMA; PRIORITY JOURNAL; SHORT SURVEY; VOMITING;

EID: 77953158446     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1003126     Document Type: Short Survey

References (4)

1. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. II. Management. Ann Rheum Dis 2006;65:1312-1324
2. Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum 2010;62:1060-1068
3. Ahern MJ, Reid C, Gordon TP, McCredie M, Brooks PM, Jones M. Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med 1987;17:301-304 (Pubitemid 18014682)
4. Mutual Pharmaceutical Co. v. Watson Pharmaceuticals, 2009 WL 3401117 (C.D. Calif., Oct. 19, 2009).